According to the clinical data published in this paper, Lianhua Qingwen can effectively improve the clinical cure rate, and has obvious therapeutic effect on symptoms such as fever, fatigue and cough, and it is safe. However, the paper shows that there is no significant difference in reducing the conversion rate of severe cases and improving the negative rate of virus detection.
In this clinical trial, there was no significant difference in the conversion rate of severe cases and the negative rate of virus detection between the two groups, and there was no significant difference in the median time of negative detection of virus. At the same time, the report showed that there were no serious adverse reactions in Lianhua Qingwen treatment group.
Extended data
Experimental results of clinical data of Lianhua Qingwen;
After 14 days of treatment (4 capsules each time, 3 times a day), the cure rate of Lianhua Qingwen treatment group reached 9 1.5%, which was significantly higher than that of the control group (82.4%). In addition, the median cure time of fever, fatigue, cough and other symptoms in Lianhua Qingwen treatment group was significantly shortened.
The study also proved that Lianhua Qingwen treatment can obviously improve the improvement rate of CT images of patients with abnormal lung and improve the overall clinical cure rate. Under the complete analysis set, the improvement rate of lung CT images in Lianhua Qingwen treatment group was 83.8%, while that in control group was 64.65438 0%. The total clinical cure rate of Lianhua Qingwen treatment group was 78.9%, while that of control group was 66.2%.
World Wide Web-Lianhua Qingwen clinical data disclosure: Zhong Nanshan led, promoting cure but not turning negative.